Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports
From: Multiple Sclerosis News Today By: Marta Figueiredo Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying therapy (DMT) continue to rise in Europe, according to a survey conducted by Spherix Global Insights…(read more)
Specialty Physicians Predict More Pain Ahead in the Battle Against COVID-19
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to the latest update from Spherix Global Insights EXTON, Pa., April 9, 2020 / PRNewswire / – Special Report: Multi-Specialty Impact of COVID-19 is an independent project being run by Spherix to assess the impact of […]
Roche’s Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis’ Mayzent and Ofatumumab May Threaten the Brand’s Long-Term Dominance
In the wake of the Mayzent EMA approval, neurologists expect to diagnose more patients with active secondary progressive multiple sclerosis to broaden the pool of patients eligible for the second-to-market S1P receptor modulator, according to Spherix Global Insights EXTON, Pa., April 9, 2020 ― Driven by expanded access to and uptake of disease-modifying therapies (DMTs) […]
COVID-19 is Bad News for New Drug Launches. Which Will Suffer Most?
From: FiercePharma By: Angus Liu COVID-19 is Bad News for New Drug Launches. Which Will Suffer Most? A recent survey by Spherix Global Insights showed that one-quarter of neurologists are less likely to prescribe a migraine therapy that has been on the market for less than a year due to the ongoing COVID-19 crisis… (read more).
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists’ Prelaunch Expectations that Biohaven’s Nurtec ODT Would Challenge Allergan’s Ubrelvy and Eli Lilly’s Reyvow
Looking to the future, the approval of the first dual-therapy migraine label would make Nurtec a substantial competitive threat on the prevention market, placing considerable stress on Amgen/Novartis’ Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Lundbeck’s Vyepti trajectories, according to Spherix Global Insights EXTON, Pa., April 2, 2020 ― Biohaven’s Nurtec (rimegepant) orally disintegrating tablet […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
With a plethora of agents in development, manufacturers who already have one leg in the dermatology biologic/small molecule space, such as AbbVie, Amgen, Eli Lilly, Janssen, and Novartis could have a competitive edge over more novel developers. EXTON, Pa., March 17, 2020 /PRNewswire/ — The past decade has ushered in an array of new treatment […]
Genentech’s Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis’ Mayzent and EMD Serono’s Mavenclad, While Biogen’s Vumerity Begins to Chip Away at the Company’s Own Tecfidera
Key label advantages related to cortical grey matter/thalamic volume loss reduction and superior safety compared to Novartis’ Gilenya will be fundamental for preferential uptake of Bristol Myers Squibb’s Zeposia (ozanimod), according to Spherix Global Insights EXTON, Pa., March 10, 2020 ― In the last year, the US multiple sclerosis (MS) market saw the introduction of […]
AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad
From: FiercePharma By: Beth Snyder Bulik AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad While Xeljanz still enjoys support from rheums given the drug’s seven-year commercial history, docs indicated Rinvoq as the most preferred JAK if only one were to be prescribed, citing safety, efficacy and breadth of data all as […]
Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS
From: Multiple Sclerosis News Today By: Ana Pena, PHD. Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS First-line use of Genentech’s Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights’ report…(read more).
